ZytoVision GmbH

International Infection Prevention Week (#IIPW) emphasizes the importance of infection prevention and control and its role in protecting public health. For humans, numerous different pathogens are known to cause infections such as bacteria, fungi or viruses. Fast and accurate detection of an infection is crucial to prevent further transmission of the infection and to treat infectious diseases correctly. This week, ZytoVision celebrates the fundamentals of infection prevention. We are delighted to help with our VisionArray system to reduce the spread of infections by a fast and reliable detection of a variety of human pathogens. #infectionprevention #IIPW

September 2024 marks the Blood Cancer Awareness Month. As professionals in the health care system for tumor diagnostics, we are aware of the importance of having reliable diagnostic tools. Blood cancer is diagnosed in over 1 million patients every year and describes more than 100 different types of cancer that affect the production and function of blood cells.  With increasing knowledge of different tumor classes in blood cancer comes the demand for more specified molecular diagnostic methods. Many subtypes of blood cancer can be diagnosed by testing for certain genetic alterations. Fluorescence in situ hybridization (FISH) is one of the most reliable methods to detect such gene alterations allowing for tumor classification and individual therapy decisions.     ZytoVision’s FISH portfolio includes over 60 probes that are routinely used to aid blood cancer diagnostics all over the world.     #bloodcancer #bloodcancerawareness #ThisIsBloodCancer

ZytoVision – 20 years anniversary This year marks a special milestone for ZytoVision - 20 incredible years of dedication, innovation, and collaboration! We want to extend our heartfelt thanks to everyone who has been part of this journey:  Our partners – Your trust and collaboration have been the key of our success. Our customers – Thank you for believing in us and driving us to deliver excellence every day. Our amazing team – Your passion, commitment, and creativity have made ZytoVision what it is today. As we celebrate the past, we're even more excited for the future. Together, we will continue to push boundaries, innovate, and create solutions that make a difference in the world of pathology and cancer diagnostics. Here's to the next 20 years of growth, progress, and partnership!

Exciting Update!    We are delighted to announce that the below mentioned probes are now officially available as IVDR-certified products. ZytoDot SPEC ERBB2 Probe  ZytoDot 2C SPEC IGH Break Apart Probe  ZytoDot 2C SPEC BCL6 Break Apart Probe    ZytoFast human lg-kappa Probe    ZytoLight SPEC MDM2/CEN 12 Dual Color Probe  ZytoLight SPEC ERBB2/CEN 17 Dual Color Probe  ZytoLight SPEC 19q13/19p13 Dual Color Probe  ZytoLight SPEC IGH Dual Color Break Apart Probe  ZytoLight SPEC RET Dual Color Break Apart Probe  ZytoLight SPEC ABL1 Dual Color Break Apart Probe This certification underscores our commitment to delivering the highest quality products. We’re continually innovating to support precise diagnoses around the world. So stay tuned for more updates!     For further information on our IVDR-certified probes, please visit our website or contact your local sales representative.

We are thrilled to announce our participation in Medlab Asia 2024! Join us as we showcase our products and solutions for clinical cancer diagnostics Our team of experts from ZytoVision GmbH and Zytomed Systems GmbH will be on site to present our product portfolio, discuss industry trends, and explore new opportunities for collaboration. We look forward to connecting with fellow professionals, industry leaders, and innovators. #MedlabAsia #HealthcareInnovation #InnovationInHealthcare #MedTech

Back in 2004, at our first labs in Berlin and Bremerhaven in Germany, a group of ambitious biologists started developing our first solutions for immunohistochemistry and in situ hybridization with a shared vision: to contribute to the pace of advanced cancer detection and characterization.   Since then, products from our stand-alone companies: Zytomed Systems, ZytoVision, 42LS and Diagomics have been present in the laboratories around the globe. With respect to our established brands, we are now moving forward, and we are growing together under the brand-new name ZYTOMICS!   Learn more under the following link: www.zytomics.com

We are thrilled to announce the successful completion of our comprehensive sales training for our international distribution partners from Mexico, Canada, Japan, and Pakistan! 🌎✨ Over the past week, we had the privilege of hosting an intensive training session that covered our entire product portfolio. From innovative in situ hybridization (ISH) solutions to our advanced molecular diagnostics tools, our partners are now better equipped than ever to represent ZytoVision in their respective markets. A huge thank you to all our dedicated partners for their enthusiasm and commitment to excellence. Your feedback and engagement were invaluable, and we are confident that this collaboration will lead to even greater successes in the future. Here’s to stronger partnerships and continued growth across borders! 🌐🚀 #ZytoVision #GlobalPartners #SalesTraining #insituhybridisation #moleculardiagnostics

From June 23-26, the 44th Annual Congress of the European Society of Mycobacteriology will be held in Bruges, Belgium. ZytoVision will be present with a booth at the conference, presenting the VisionArray MYCO Chip 2.0 (and other exciting products). The VisionArray MYCO Chip was designed to detect several different types of clinically relevant mycobacterial species. The VisionArray MYCO Chip 2.0 is used with the corresponding VisionArray MYCO PreCise MasterMix 2.0 and a VisionArray Analysis Software for a fast and reliable detection. For further information on the VisionArray system, visit our booth at the conference or our website. #zytovision #visionarray #mycobacteriology #pathogendetection

We are delighted to invite you to our upcoming webinar on the role of in situ hybridization (ISH) in lymphoma and leukemia diagnostics. Approximately 8% of the new cancer cases diagnosed worldwide are leukemia, lymphoma, and myeloma. Genetic analysis contributes to the diagnosis and/or management of nearly every form of hematologic malignancy. The in situ hybridization method plays a crucial role in the determination of specific chromosomal aberrations that could otherwise not be detected by e.g. conventional karyotyping. ISH is a very useful, specific, and reliable tool that is helpful for differential diagnosis and may thus guide therapy management in patients with hematopoietic and lymphoid neoplasms. Register now to secure your spot!  #zytovision #fish #insituhybridization #cancer #lymphoma #leukemia #moleculardiagnostics